Celiac Disease: Promising Biomarkers for Follow-Up

J 2023

Celiac Disease: Promising Biomarkers for Follow-Up

HRUNKA, Matěj, Lubomír JANDA, Michaela ŠŤASTNÁ, Tereza PINKASOVÁ, Jakub PECL et. al.

Základní údaje

Originální název

Celiac Disease: Promising Biomarkers for Follow-Up

Autoři

HRUNKA, Matěj (203 Česká republika, domácí), Lubomír JANDA (203 Česká republika), Michaela ŠŤASTNÁ (203 Česká republika), Tereza PINKASOVÁ (203 Česká republika, domácí), Jakub PECL (203 Česká republika, domácí), Lumír KUNOVSKÝ (203 Česká republika, domácí), Petr DÍTĚ (203 Česká republika, domácí) a Petr JABANDŽIEV (203 Česká republika, domácí)

Vydání

Journal of gastrointestinal and liver diseases : JGLD, CLUJ-NAPOCA, MEDICAL UNIV PRESS, 2023, 1841-8724

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30219 Gastroenterology and hepatology

Stát vydavatele

Rumunsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.100 v roce 2022

Kód RIV

RIV/00216224:14110/23:00132727

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.15403/JGLD-4926

UT WoS

001158173500017

Klíčová slova anglicky

celiac disease; novel biomarkers; microRNAs; gluten immunogenic peptide; citrulline; IgA deficiency

Štítky

14110213, 14110223, 14110317, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 3. 2024 07:31, Mgr. Tereza Miškechová

Anotace

V originále

Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients’ adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.

Citovat

HRUNKA, Matěj, Lubomír JANDA, Michaela ŠŤASTNÁ, Tereza PINKASOVÁ, Jakub PECL, Lumír KUNOVSKÝ, Petr DÍTĚ a Petr JABANDŽIEV. Celiac Disease: Promising Biomarkers for Follow-Up. Journal of gastrointestinal and liver diseases : JGLD. CLUJ-NAPOCA: MEDICAL UNIV PRESS, 2023, roč. 32, č. 4, s. 536-544. ISSN 1841-8724. Dostupné z: https://dx.doi.org/10.15403/JGLD-4926.

@article{2355298,
   author = {Hrunka, Matěj and Janda, Lubomír and Šťastná, Michaela and Pinkasová, Tereza and Pecl, Jakub and Kunovský, Lumír and Dítě, Petr and Jabandžiev, Petr},
   article_location = {CLUJ-NAPOCA},
   article_number = {4},
   doi = {http://dx.doi.org/10.15403/JGLD-4926},
   keywords = {celiac disease; novel biomarkers; microRNAs; gluten immunogenic peptide; citrulline; IgA deficiency},
   language = {eng},
   issn = {1841-8724},
   journal = {Journal of gastrointestinal and liver diseases : JGLD},
   title = {Celiac Disease: Promising Biomarkers for Follow-Up},
   url = {https://jgld.ro/jgld/index.php/jgld/article/view/4926},
   volume = {32},
   year = {2023}
}

TY  - JOUR
ID  - 2355298
AU  - Hrunka, Matěj - Janda, Lubomír - Šťastná, Michaela - Pinkasová, Tereza - Pecl, Jakub - Kunovský, Lumír - Dítě, Petr - Jabandžiev, Petr
PY  - 2023
TI  - Celiac Disease: Promising Biomarkers for Follow-Up
JF  - Journal of gastrointestinal and liver diseases : JGLD
VL  - 32
IS  - 4
SP  - 536-544
EP  - 536-544
PB  - MEDICAL UNIV PRESS
SN  - 18418724
KW  - celiac disease
KW  - novel biomarkers
KW  - microRNAs
KW  - gluten immunogenic peptide
KW  - citrulline
KW  - IgA deficiency
UR  - https://jgld.ro/jgld/index.php/jgld/article/view/4926
N2  - Celiac disease is a common gastroenterological illness. Current diagnostics of the disease are based on serological markers and histology of duodenal biopsies. Hitherto, a strict gluten-free diet is the only effective treatment and is necessary for good control of the disease. Serological tests in current use have very high specificity and sensitivity for diagnostics, but in follow-up they have some limitations. Their levels do not accurately reflect mucosal healing, and they are unable to detect minimal transgressions in the diet. This problem is significant in patients with IgA deficiency, and there exist no robust follow-up tools for monitoring these patients’ adherence to treatment. For their follow-up, we currently use IgG-based tests, and these antibodies persist for a long time even when a patient has stopped consuming gluten. More accurate and specific biomarkers are definitely needed. Adherence to a gluten-free diet is essential not only for intestinal mucosa healing and alleviation of symptoms but also for preventing complications associated with celiac disease. Here, we summarize current evidence regarding noninvasive biomarkers potentially useful for follow-up not only of patients with IgA deficiency but for all patients with celiac disease. We describe several very promising biomarkers with potential to be part of clinical practice in the near future.
ER  -

HRUNKA, Matěj, Lubomír JANDA, Michaela ŠŤASTNÁ, Tereza PINKASOVÁ, Jakub PECL, Lumír KUNOVSKÝ, Petr DÍTĚ a Petr JABANDŽIEV. Celiac Disease: Promising Biomarkers for Follow-Up. \textit{Journal of gastrointestinal and liver diseases : JGLD}. CLUJ-NAPOCA: MEDICAL UNIV PRESS, 2023, roč.~32, č.~4, s.~536-544. ISSN~1841-8724. Dostupné z: https://dx.doi.org/10.15403/JGLD-4926.

Podrobný výpis o publikaci